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Background: Cardiac hypertrophic remodelling and systolic dysfunction are common in patients with mito-
chondrial disease and independent predictors of morbidity and early mortality. Endurance exercise training
improves symptoms and skeletal muscle function, yet cardiac adaptations are unknown.
Methods and results: Before and after 16-weeks of training, exercise capacity, cardiac magnetic resonance
imaging and phosphorus-31 spectroscopy, disease burden, fatigue, quality of life, heart rate variability
(HRV) and blood pressure variability (BPV) were assessed in 10 adult patients with m.3243A>G-related
mitochondrial disease, and compared to age- and gender-matched sedentary control subjects. At baseline,
patients had increased left ventricular mass index (LVMI, p b 0.05) and LV mass to end-diastolic volume
ratio, and decreased longitudinal shortening and myocardial phosphocreatine/adenosine triphosphate ratio
(all p b 0.01). Peak arterial–venous oxygen difference (p b 0.05), oxygen uptake (VO2) and power were
decreased in patients (both p b 0.01) with no signiﬁcant difference in cardiac power output. All patients
remained stable and completed ≥80% sessions. With training, there were similar proportional increases in
peak VO2, anaerobic threshold and work capacity in patients and controls. LVMI increased in both groups
(p b 0.01), with no signiﬁcant effect on myocardial function or bioenergetics. Pre- and post-exercise training,
HRV and BPV demonstrated increased low frequency and decreased high frequency components in patients
compared to controls (all p b 0.05).
Conclusion: Patients with mitochondrial disease and controls achieved similar proportional beneﬁts of
exercise training, without evidence of disease progression, or deleterious effects on cardiac function. Reduced
exercise capacity is largely mediated through skeletal muscle dysfunction at baseline and sympathetic over-
activation may be important in pathogenesis.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.lcome Trust [BH092142 to MGDB, 096919Z/11/Z and 074454/Z/04/Z to DMT and RWT]; the Medical Research Council
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Mitochondrial diseases are a heterogeneous group of genetic dis-
orders resulting in signiﬁcant morbidity and disability, and affecting
up to 8000 adults in the UK [1]. The m.3243A>G mutation in the
mt-tRNALeu(UUR) MTTL1 gene is the most common pathogenic muta-
tion, present in ~1 in 300 of the general population and causing
disease in ~1 in 6000 individuals [2]. The clinical phenotype is highly
variable: originally described in patients with mitochondrial en-
cephalopathy, lactic acidosis and stroke-like episodes (MELAS), the
m.3243A>G mutation can also cause maternally inherited diabetes
and deafness (MIDD), myopathy, ophthalmoplegia and cardiomyop-
athy, as isolated clinical features or part of multisystem disease [3].
Despite this phenotypic variability, exercise intolerance and fatigue
are common clinical symptoms.
There are currently limited therapeutic options for patients with
mitochondrial disease [4]. Endurance exercise training has, however,
been demonstrated to improve exercise tolerance, quality of life and
skeletal muscle oxidative capacity in this patient group, reversing
baseline de-conditioning [5–8]. Resistance exercise training has been
linked to similar clinical improvements in patientswithmitochondrial
disease [9]. While the cellular mechanisms underlying the effects of
exercise training are yet to be fully elucidated, no deleterious clinical
outcomes related to skeletal muscle function, quality of life or disease
progression have been reported in studies from diverse genotypic
groups. Yet clinical equipoise exists with regard to cardiac parameters,
and understandable concerns of adverse remodelling, in a cohort of
patients prone to cardiac abnormalities, may have restricted thewide-
spread uptake of therapeutic endurance exercise training in patients
withmitochondrial disease, hampering clinical care. Cardiomyopathy,
most commonly with a hypertrophic phenotype, occurs in 20–40% of
patients carrying the m.3243A>G mutation [10–14], and is an inde-
pendent predictor of morbidity and early mortality [13,15]. Impaired
cardiac bioenergetics also occur in patients with m.3243A>G-related
mitochondrial disease [16,17], and are predictive of prognosis in diverse
forms of cardiomyopathy [18]. Cardiovascular autonomic dysfunction
has been demonstrated in patients harbouring the m.3243A>G muta-
tion [19,20], and is independently associated with an increased risk
of sudden death in the general population, after myocardial infarction
[21].
In untrained individuals without mitochondrial disease, endur-
ance exercise training increases left ventricular mass, ventricular
cavity dimensions and haemodynamic parameters of cardiac function
[22–24]. Similarly, exercise in patients with established heart failure
reduces symptoms and improves cardiac function, exercise tolerance,
quality of life and daily activity levels,without a signiﬁcant deleterious
effect on impaired cardiac bioenergetics [25–27]. However whether
similar effects occur in patients with mitochondrial disease is un-
known.Magnetic resonance imaging (MRI) is the gold standard inves-
tigation of cardiac morphology and, combined with cardiac tagging
and phosphorus-31 (31P) magnetic resonance spectroscopy (MRS)
enables detection of subclinical defects in both myocardial deforma-
tion and bioenergetics. Using these modalities, we sought to charac-
terize the effects of endurance exercise training on disease burden,
resting cardiac function, high energy phosphate metabolism, cardio-
vascular autonomic function, fatigue and quality of life in a clinically
and genetically well-characterized cohort of patients with m.3243A>G-
related mitochondrial disease with reference to age- and gender- and
habitual physical activity level-matched controls.
2. Methods
2.1. Participants
Ten patients with mitochondrial disease due to the m.3243A>G mutation, but
without known cardiac involvement, were recruited from consecutive attendees at a
specialist outpatient clinic between August 2010 and July 2011. All eligible patientswere verbally invited to participate in the study based on the following clinical inclu-
sion criteria: (i) clinical stability for >6 months; (ii) ability to use a semi-recumbent
stationary bicycle ergometer; and (iii) no current participation in regular physical
activity (≥1 weekly session). Exclusion criteria were the presence of known cardiac
involvement (determined using clinical history, examination, 12-lead ECG and echo-
cardiogram), comorbidities precluding exercise training (e.g. osteoarthritis), and
contra-indications to MRI, including the presence of a pacemaker or implantable
cardioverter-deﬁbrillator, abnormal renal function (eGFR b60 ml/min/1.73 m2) or
claustrophobia. All 10 patients were matched with respect to age, gender and physical
activity level with untrained healthy controls with normal ECG and no history of car-
diovascular or metabolic disease, recruited through local advertisement. Institutional
ethical approval and written informed consent were obtained.
2.2. Assessments
All baseline and follow-up assessments were completed on a single day. Assess-
ments of exercise parameters, autonomic function, resting venous lactate and creatine
kinase (CK) were performed between 0800 and 1000 following an overnight fast
(>10 h), and cardiac MRI took place at the same time of day throughout the study for
each subject. All subjects were asked to refrain from smoking, alcohol ingestion, phys-
ical exertion and medications that could inﬂuence haemodynamic, exercise or auto-
nomic parameters (including β blockers, calcium channel blockers, anti-depressants)
for 24 h prior to assessment.
2.3. Exercise testing
Cardiopulmonary exercise testing was performed using analysis of expired air
gases (Metalyzer 3B; Cortex, Leipzig, Germany) and non-invasive bioreactance cardiac
output (NICOM; Cheetah Medical, Maidenhead, UK) on a calibrated, electronically
braked stationary bicycle ergometer (Corival®; Lode, Groningen, Netherlands) at
a steady cadence between 60 and 80 bpm. During all visits, a stepped incremental
workload test (~10–20 W/min) was conducted to elicit a symptom-limited maximum
oxygen uptake and heart rate response. Respiratory gas exchange data were collected
continuously and the Borg Rating of Perceived Exertion (RPE) score performed every
3 min. Exercise was terminated when subjects developed severe dyspnoea or periph-
eral muscle fatigue and were physically exhausted (as indicated by respiratory ex-
change ratio (RER) >1.1, Borg RPE score >18 or absence of rise in oxygen
consumption with further increases in exercise intensity). Anaerobic threshold was de-
termined using the V-slope method, as previously described [28]. Baseline physical ac-
tivity was assessed using an armband accelerometer SenseWear® Armbandmulti-array
physical activity monitor (Bodymedia, Pittsburgh, USA) worn for seven days.
Cardiac power output (in Watts) was calculated as the product of mean arterial
pressure (in mm Hg), cardiac output (in litres/min) and the conversion factor
2.22 × 10−3 [29]. Arterial–venous oxygen difference, expressed in ml O2/100 ml of
blood, was calculated as the ratio of peak oxygen consumption and cardiac output.
2.4. Disease burden
Subjects underwent physical examination by experienced clinicians (GSG and
MGDB). Disease burden in patients was assessed using the Newcastle Mitochondrial
Disease Adult Scale (NMDAS), a validated rating system [30], whilst mutation load
was determined in urinary epithelial cells, an established marker of clinical status in
patients with the m.3243A>G mutation [31].
2.5. Body weight and composition
Subject heights were recorded for body mass index and body surface area calcula-
tions. Body weights, body fat percentages and lean body weights were measured using
air displacement plethysmography (BODPOD®; COSMED, Rome, Italy).
2.6. Cardiac magnetic resonance imaging
Using a 3-Tesla scanner, cardiac MRI was performed to include: (i) 31P MRS
(ii) cine imaging, and (iii) cardiac tagging, as previously described and validated in
this patient cohort [17,32].
2.6.1. Cardiac 31P MRS
Subjects were scanned prone with a 31P surface coil using a cardiac-gated,
1-dimensional chemical shift imaging sequence. Sixteen coronal phase-encoding
steps (TR = heart rate, 192 averages) yielded spectra from 10 mm slices. The ﬁrst
spectrum arising entirely beyond the chest wall was analysed using AMARES time do-
main ﬁt [33] to quantify phosphocreatine (PCr), the γ resonance of adenosine triphos-
phate (ATP), corrected for blood contamination, and their ratio (PCr/ATP), as a marker
of cardiac bioenergetics [17].
2.6.2. Cardiac cine imaging
Subjects were scanned supine with steady-state free precession images, using a
6-channel cardiac coil and ECG gating [ﬁeld of view (FOV) 350 × 350 mm2, repetition
time/echo time (TR/TE) = 3.7/1.9 ms, turbo factor 17, ﬂip angle (FA) 40°, slice thickness
Table 1
Baseline characteristics.
Characteristic Patients
(n = 10)
Controls
(n = 10)
p value
Age (years) 42.4 ± 10.5 39.0 ± 11.8 0.391
Male sex, n (%) 6 (60) 6 (60) 1.000
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ic parameters were calculated as previously described [17,32].
2.6.3. Cardiac tagging
MR signal frommyocardium in diastole was cancelled in a rectangular grid pattern
and tags were tracked through the cardiac cycle (Fig. 1A) [34]. A multi-shot turbo-ﬁeld
echo sequence was used (TR/TE/FA/number of averages = 4.9/3.1/10°/1, turbo factor
9, SENSE factor 2, FOV 350 × 350 mm2, voxel size 1.37 mm, tag spacing 7 mm, 12
phases). Peak circumferential strain for both the whole myocardial wall and the endo-
cardial third were calculated. Peak torsion between two adjacent short-axis slices was
calculated as the circumferential-longitudinal shear angle, deﬁned on the epicardial
surface (Fig. 1B).
2.7. Autonomic function
2.7.1. Apparatus
All participants underwent assessment of autonomic function over 30 min at rest in
a cardiorespiratory laboratory using the Task Force Monitor (TFM; CNSystems, Graz,
Austria), which provides automated and computed beat-to-beat analysis of heart rate
and blood pressure. Biological inputs to the system are provided by: (i) 3-lead ECG;
(ii) impedance cardiography; and (iii) continuous, non-invasive blood pressure,
recorded using ﬁnger plethysmography with intermittently calibration to contralateral
oscillometric blood pressure measurements. From these data, the TFM calculates con-
tinuous, reliable measurements of haemodynamic and autonomic parameters [35–37].
2.7.2. Heart rate variability (HRV) and blood pressure variability (BPV)
Power spectral analysis for HRV and BPV was conducted using an adaptive
auto-regressive (AAR) model as previously described [38]. In addition to total power
spectral density (PSD), the low frequency (LF, 0.05–0.17 Hz) and high frequency (HF,
0.17–0.4 Hz) components of the signal were automatically calculated using the TFM.
All components are reported in normalized units (nu) for RR interval (RRI), systolic
blood pressure (SBP) and diastolic blood pressure (DBP) parameters (LFnu-RRI,
HFnu-RRI, LFnu-SBP, HFnu-SBP, LFnu-DBP, and HFnu-DBP). As previously described,
all LF components refer to sympathetic modulation of the sinus node activity and
vasomotor function, while HF components refer to parasympathetic modulation of
such cardiovascular activity. The ratios of LF and HF components provide a marker of
sympatho-vagal balance (LF:HF-RRI, LF:HF-SBP, and LF:HF-DBP) [39,40].
2.8. Fatigue and quality of life
Standard, validated self-completion questionnaires were used for the assessment
of fatigue (Fatigue Impact Scale (FIS)) and quality of life (the Short-Form 12 (SF-12)).
2.9. Exercise intervention
Participants were instructed to perform 30 min of cycling (excluding 5 min of
warming-up and cooling-down) on an upright ergometer, three times per week,
for 16 weeks at a self-regulated workload that achieved a heart rate corresponding
to 70–80% of the symptom-limited maximum oxygen uptake, and a Borg RPE score
12–14. Target heart rate for all subjects was monitored using an RS100 watch (Polar
Electro, Finland) and adjusted at 8 weeks following completion of a maximal graded
cardiopulmonary exercise test. Workload was adjusted continuously during all train-
ing sessions to achieve target heart rates. Participants were asked to limit training to
the prescribed programme, and, although exercise training was unsupervised, allFig. 1. Cardiac tagging analysis. (A) Cine imaging (top panels) and tagging (bottom)
at end-diastole (left panels) and end-systole (right). A rectangular grid of nulled myo-
cardium applied in diastole enables tracking of myocardial deformation, including
circumferential strain. (B) Tagging of 2 parallel short-axis slices allows calculation of
torsion, the longitudinal–circumferential sheer angle (θ) as shown. Torsion describes
the twisting motion of the heart due to opposite rotation of base and apex, and main-
tains homogeneity of strain across the myocardial wall. Increased torsion results from
dominant contractile function in the subepicardium, compared to the subendocardium
such that the torsion to endocardial circumferential strain ratio (TSR) is a sensitive
marker of altered epicardial–endocardial interaction.subjects received weekly phone calls to ensure compliance with exercise training, and
completed exercise diaries that were regularly reviewed by study investigators.
2.10. Statistical analysis
Data are presented as means ± SD for continuous data and as numbers or percent-
ages for categorical data. Continuous data were tested for normality, linearity and ho-
mogeneity of covariance matrices. A mixed model multivariate analysis of variance
was performed between patients and controls, before and after completion of the
exercise intervention. Group (patient or control) and time (baseline or follow-up)
were respected as factors and physiological parameters were taken as the dependent
variables. The interaction between group and time conditions permitted detection of
any differences in the response to exercise. Where the mixed model main factors or
interaction were statistically signiﬁcant, subsequent between group comparisons were
made using unpaired Student's t-tests or Mann–Whitney U tests and within group com-
parisons using paired Student's t-tests orWilcoxon signed rank tests. Categorical variables
were compared using Fisher's exact test and correlations were executed using Pearson's
method. All analysis was performed using SPSS version 17 (SPSS Inc., Chicago, Illinois).
All tests were two-sided and statistical signiﬁcance was assumed at p b 0.05.
3. Results
3.1. Patient group characteristics
The baseline characteristics of 10 patients (9 probands) and 10 con-
trol subjects, matched for age, gender and habitual physical activity, are
presented in Table 1. Body mass index (BMI) and body surface area
(BSA)were signiﬁcantly lower in patients than controls. Cardiovascular
disease features and relevant medications are included in Table 1: ﬁve
patients had diabetes mellitus and one had treated hypertension.
There were no signiﬁcant differences in current systolic or diastolic
blood pressures.
Patient details including speciﬁc clinical features, mutation loads
and baseline NMDAS, FIS and SF-12 scores are presented in Table 2.
Disease burden was mild or moderate in all patients with phenotypes
consistent with MIDD (ﬁve patients), myopathy (three patients),
MELAS (one patient) and oligosymptomatic status (one patient). The
frequencies of speciﬁc clinical features in this group are presented in
Supplementary Table 1. Fatigue was a clinical feature of mitochondrial
disease in ﬁve patients (50%): three patients reported excessive fatigue
(FIS score≥40) and onepatient reported severe fatigue (FIS score≥80).Height (cm) 171 ± 10 172 ± 10 0.707
Weight (kg) 62.1 ± 12.2 81.9 ± 12.9 0.002
Body mass index (kg/m2) 21.3 ± 3.4 27.7 ± 4.7 0.002
Body surface area (m2) 1.72 ± 0.19 1.95 ± 0.16 0.010
Habitual physical activity
Daily energy expenditure (kCal) 2133 ± 666 2529 ± 373 0.118
Daily steps (n) 7949 ± 3968 9290 ± 2708 0.207
Diabetes mellitus, n (%) 5 (50) 0 (0) N/A
Hypertension, n (%) 1 (10) 0 (0) N/A
Cardiac clinical parameters
Heart rate (min−1) 75 ± 11 64 ± 10 0.033
SBP (mm Hg) 118 ± 11 114 ± 8 0.430
DBP (mm Hg) 81 ± 8 77 ± 7 0.181
Selected medications
ACE inhibitor/ARB 4 (40) 0 (0) N/A
Beta-blocker 0 (0) 0 (0) N/A
Calcium channel blocker 1 (10) 0 (0) N/A
Insulin 3 (30) 0 (0) N/A
Metformin 2 (20) 0 (0) N/A
Statin 4 (40) 0 (0) N/A
Co-enzyme Q10 4 (40) 0 (0) N/A
Antidepressant 2 (20) 0 (0) N/A
N/A = not applicable; SBP = systolic blood pressure; DBP = diastolic blood pressure;
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker.
Table 2
Disease features of patients.
Patient Age Sex Urinary m.3243A>G
mutation load (%)
Clinical features Baseline clinical scores
NMDAS FIS SF-12
PHC
SF-12
MHC
1a 39 M 80 SNHL, diabetes mellitus, exercise intolerance, ataxia, migraine, GIT, fatigue, hypothyroidism 17 44 38 37
2 58 F 59 SNHL, exercise intolerance, mild ataxia, proximal muscle weakness, GIT, low BMI, myalgia 12 2 56 58
3a 42 M 82 SNHL, diabetes mellitus, exercise intolerance, ataxia, migraine, depression 12 9 50 59
4 47 M 63 SNHL, diabetes mellitus, exercise intolerance, ataxia, proximal and distal muscle weakness,
depression, fatigue, myalgia, PEO, ptosis, sensory neuropathy
28 109 23 29
5 37 F 48 SNHL, diabetes mellitus, exercise intolerance, mild ataxia, mild dysarthria, asthma 10 13 52 53
6 38 F 53 SNHL, exercise intolerance, proximal muscle weakness, fatigue, migraine, GIT, asthma 13 29 32 55
7 22 M 89 SNHL, exercise intolerance, ataxia, fatigue, migraine, GIT, low BMI, epilepsy 18 62 40 46
8 36 M 80 Exercise intolerance, migraine 4 9 57 54
9 50 M 87 SNHL, exercise intolerance, ataxia, proximal and distal muscle weakness, fatigue, depression,
retinopathy, epilepsy, encephalopathy, cognitive decline, stroke-like episodes
23 68 57 46
10 55 F 68 SNHL, diabetes mellitus, exercise intolerance, ataxia, proximal muscle weakness, GIT, depression,
retinopathy, PEO, ptosis, short stature, mild dysphagia, hypertension
25 23 36 49
NMDAS = Newcastle Mitochondrial Disease Adult Scale; M = male; F = female; MIDD = maternally inherited deafness and diabetes; MELAS = mitochondrial encephalopathy,
lactic acidosis and stroke-like episodes; FIS = Fatigue Impact Scale; SF-12 = Short Form-12 quality of life questionnaire; PHC = physical health component; MHC = mental
health component .
a Sibling.
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All patients and control subjects completed≥80% of the 48 scheduled
training sessions, and no adverse events were reported. All patients
remained clinically stable throughout the study, and there were no
changes in medication.
Cardio-pulmonary exercise testing responses for patients and con-
trols before and after completion of the exercise training programme
are presented in Table 3. There was no signiﬁcant effect of subject
status (patient or control) on the response to endurance exercise in
any haemodynamic, exercise physiology or cardiac parameter.
3.3. Haemodynamic parameters
At peak exercise stroke volume, heart rate, cardiac output, and car-
diac index,were all decreased in patients compared to controls (Table 3),Table 3
Exercise parameters before and after training.
Parameter Patients
Baseline Follow-up p valuea
Peak exercise
Heart rate 167 ± 21 161 ± 18 0.299
SBP (mm Hg) 183 ± 24 193 ± 21 0.082
DBP (mm Hg) 94 ± 17 93 ± 15 0.880
MAP (mm Hg) 124 ± 15 126 ± 13 0.535
Stroke volume (ml) 91 ± 23 95 ± 29 0.532
Stroke index (ml/m2) 53 ± 9 54 ± 12 0.687
Cardiac output (l/min) 14.5 ± 3.9 15.1 ± 4.8 0.398
Cardiac index (l/min/m2) 8.3 ± 1.5 8.6 ± 2.1 0.681
VO2 (ml/min) 1382 ± 625 1596 ± 726 0.030
VO2 (ml/kg/min) 21.4 ± 6.3 24.8 ± 8.9 0.009
VO2 (% predicted VO2) 61 ± 20 72 ± 25 0.011
CPO 4.0 ± 1.3 4.0 ± 1.2 0.708
CPOI 2.3 ± 0.5 2.3 ± 0.5 0.732
Power (W) 100 ± 45 112 ± 55 0.044
A–VO2 diff (ml O2/dl) 9.4 ± 3.0 10.5 ± 3.1 0.059
Anaerobic threshold
ATVO2 (ml/kg/min) 13.4 ± 5.0 16.5 ± 6.4 0.014
ATVO2 (% predicted peak VO2) 38 ± 14 47 ± 18 0.221
ATVO2 (% recorded peak VO2) 61 ± 8 66 ± 5 0.128
SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arterial pres
CPOI = cardiac power output index; A–VO2 diff = arterial–venous oxygen difference; AT =
a p value represents the within group comparison of paired before and follow-up time p
b p value represents group by time interaction from mixed model repeated measures an
⁎ p b 0.05 for patients vs. controls at equivalent time points.
⁎⁎ p b 0.01 for patients vs. controls at equivalent time points.achieving statistical signiﬁcance at either baseline or follow-up or both
time-points for each of these parameters. There were no signiﬁcant dif-
ferences between the groups in peak systolic, diastolic or mean arterial
blood pressures or in cardiac power output, when indexed to BSA (CPO
index). Although there was a trend towards reduction in peak heart
rate following exercise training in both groups, this only achieved statis-
tical signiﬁcance in controls (mean decrease 7 bpm, p = 0.001).
3.4. Exercise physiology
At baseline, peak VO2, peak arterial–venous oxygen difference
(A–VO2 diff), and peak power were all signiﬁcantly decreased in pa-
tients compared to controls (mean decreases 22%, 30%, 23% and 77% re-
spectively). The anaerobic threshold (AT) at baseline, when expressed
as a percentage of predicted peak VO2, was signiﬁcantly decreased
in patients compared to controls, while absolute values showed aControls Interaction p valueb
Baseline Follow-up p valuea
184 ± 17 178 ± 14⁎ 0.001 0.921
188 ± 18 194 ± 16 0.183 0.744
99 ± 12 89 ± 17 0.069 0.222
129 ± 10 124 ± 13 0.260 0.258
116 ± 20⁎⁎ 118 ± 26 0.774 0.786
59 ± 9 60 ± 9 0.832 0.695
21.3 ± 4.1⁎⁎ 21.0 ± 4.8⁎ 0.946 0.643
10.6 ± 1.2⁎⁎ 10.4 ± 1.5 0.828 0.517
2276 ± 670⁎⁎ 2525 ± 562⁎ 0.049 0.983
27.6 ± 6.3⁎ 30.4 ± 5.9 0.047 0.965
94 ± 21⁎⁎ 106 ± 26⁎⁎ 0.032 0.882
5.7 ± 1.0⁎⁎ 5.4 ± 1.2⁎ 0.408 0.413
2.7 ± 0.4 2.8 ± 0.5 0.396 0.294
177 ± 40⁎⁎ 200 ± 39⁎⁎ 0.001 0.621
10.9 ± 2.9⁎ 11.8 ± 1.9⁎ 0.242 0.736
15.4 ± 4.1 18.8 ± 4.1 0.017 0.772
53 ± 14⁎ 65 ± 19⁎⁎ 0.032 0.665
56 ± 7 63 ± 5 0.049 0.758
sure; VO2 = oxygen uptake; AT = anaerobic threshold; CPO = cardiac power output;
anaerobic threshold.
oints.
alysis.
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groups, sixteen weeks of endurance exercise training signiﬁcantly in-
creased peak work capacity (power, 12% and 13% respectively), peak
oxygen uptake (VO2, 16% and 10%), and anaerobic threshold (AT, 23%
and 23%) without a signiﬁcant change in CPO or CPOI. In patients,
there was a non-signiﬁcant trend towards an increase in peak capacity
for oxygen extraction (A–VO2 diff, 12%, p = 0.059). Resting venous lac-
tate and creatine kinase were not signiﬁcantly different at baseline be-
tween patients and controls and there was no signiﬁcant effect of
endurance exercise training on these blood parameters, in either
group (Supplementary Table 2).
3.5. Body composition
Although signiﬁcant between-group differences existed at baseline,
there were no signiﬁcant changes in body weight or BMI in patient
or control groups in response to exercise training (Supplementary
Table 2). In patients, there was a non-signiﬁcant trend towards an in-
crease in lean bodyweight (mean increase 1.0 kg, p = 0.056) following
the endurance exercise training intervention.
3.6. Cardiac structure and function
Table 4 summarizes the cardiac MRI structural and functional pa-
rameters for patient and control groups. The means and ranges of con-
trol group parameters are in agreement with a large cohort study using
quantitative cardiac MRI [41].
At baseline, end-systolic and end-diastolic cardiac volumes were
proportionally decreased in patients compared to controls, with no
difference in ejection fraction (Table 4). Stroke volume was also
decreased in patients: this occurred in association with an increase
in heart rate (r = −0.71, p = 0.021), with no difference in cardiacTable 4
Cardiac parameters before and after exercise training.
Parameter Patients
Baseline Follow-up p value
Structure and systolic function
EDV (ml) 96 ± 21 101 ± 17 0.120
EDI (ml/m2) 55 ± 8 58 ± 6 0.138
ESV (ml) 38 ± 13 41 ± 13 0.158
ESI (ml/m2) 22 ± 6 23 ± 6 0.184
SV (ml) 58 ± 9 60 ± 6 0.342
SI (ml/m2) 33 ± 3 35 ± 3 0.340
CO (l/min) 4.3 ± 0.7 4.2 ± 0.7 0.502
CI (l/min/m2) 2.5 ± 0.2 2.4 ± 0.4 0.419
EF (%) 61 ± 5 60 ± 7 0.515
LS (%) 14.8 ± 0.2 13.2 ± 0.3 0.213
LVM (g) 124 ± 20 140 ± 21 0.003
LVMI (g/m2) 72 ± 13 81 ± 10 0.004
M/V ratio (g/ml) 1.35 ± 0.40 1.41 ± 0.26 0.302
Diastolic function
E/A ratio 1.65 ± 0.62 1.45 ± 0.57 0.387
EFP (%) 67.7 ± 6.7 70.7 ± 14.1 0.468
Tagging and strains
Torsion (°) 9.1 ± 3.5 7.9 ± 1.0 0.337
Whole wall circumferential strain (%) 16.4 ± 1.9 16.7 ± 1.4 0.624
Endocardial circumferential strain (%) 20.6 ± 2.0 20.0 ± 2.0 0.353
TSR (rad) 0.80 ± 0.38 0.71 ± 0.10 0.555
Cardiac high energy phosphates
PCr/ATP ratio 1.45 ± 0.42 1.61 ± 0.39 0.260
EDV = end-diastolic volume; ESI = end-diastolic index; ESV = end-systolic volume; ESI
CI = cardiac index; EF = ejection fraction; LS = longitudinal shortening; LVM = left vent
mass to volume; E/A ratio = ratio of early to late ventricular ﬁlling velocity; EFP = early ﬁ
ATP = adenosine triphosphate.
a p value represents the within group comparison of paired before and follow-up time p
b p value represents group by time interaction from mixed model repeated measures an
⁎ p b 0.05 for patients vs. controls at equivalent time points.
⁎⁎ p b 0.01 for patients vs. controls at equivalent time points.output. Endurance exercise had no signiﬁcant effect on cardiac volumes
or global systolic or diastolic function in patients or controls.
LV mass index (LVMI) was signiﬁcantly increased in patients com-
pared to controls (Table 4) at baseline, but remained within the normal
range, as LVMI did not fulﬁl the deﬁnition of left ventricular hypertro-
phy (LVH) in any patient. A signiﬁcant increase in M/V ratio (57%,
p = 0.001) suggested that this subclinical difference represented con-
centric remodelling. Cardiacmass increased signiﬁcantly in both patient
and control groups following endurance exercise, with similar propor-
tional sizes of effect: LVM (mean increases 13% and 16% respectively,
Fig. 2), LVMI (13% and 17%), and M/V ratio (5% and 10%). Subject status
(patient or control) had no signiﬁcant effect on the effect of exercise on
LVMI (Fig. 3A).
3.7. Cardiac tagging and myocardial strains
At baseline, there was evidence of alteredmyocardial strains in pa-
tients consistent with subclinical concentric remodelling (Table 4):
longitudinal shortening was signiﬁcantly decreased (18%) and corre-
lated signiﬁcantly with increased LVMI (r = −0.61, p = 0.03). Peak
torsion was increased (54%) and endocardial circumferential strain
was decreased (17%) in patients compared to controls, with a subse-
quent signiﬁcant increase in their ratio, the TSR (95%). There were,
however, no signiﬁcant effects of exercise on myocardial strains or
torsion in either patients or controls.
3.8. Myocardial bioenergetics
At baseline, PCr/ATP ratio was decreased in patients compared to
controls (mean decrease 26%, p = 0.002, Table 4). Seven patients
(70%) but no controls had an abnormal PCr/ATP ratio (b1.6) [18],
but there was no signiﬁcant difference in markers of disease burden,Controls Interaction p valueb
a Baseline Follow-up p valuea
136 ± 25⁎⁎ 139 ± 20⁎⁎ 0.305 0.737
69 ± 10⁎⁎ 71 ± 8⁎⁎ 0.224 0.992
56 ± 13⁎⁎ 56 ± 14⁎ 0.972 0.551
29 ± 5⁎ 29 ± 6 0.898 0.646
79 ± 14⁎⁎ 83 ± 10⁎⁎ 0.354 0.926
41 ± 6⁎⁎ 43 ± 5⁎⁎ 0.281 0.537
5.0 ± 1.0 5.1 ± 1.0 0.755 0.843
2.6 ± 0.4 2.7 ± 0.5 0.689 0.528
59 ± 4 60 ± 6 0.489 0.410
18.1 ± 0.2⁎⁎ 17.3 ± 0.3⁎ 0.553 0.573
116 ± 20 134 ± 26 0.001 0.989
59 ± 8⁎ 69 ± 11⁎ 0.002 0.666
0.86 ± 0.07⁎⁎ 0.97 ± 0.11⁎⁎ 0.003 0.620
1.65 ± 0.40 1.83 ± 0.43 0.320 0.451
72.7 ± 7.6 73.9 ± 6.4 0.698 0.557
5.9 ± 1.9⁎ 6.7 ± 1.5⁎ 0.057 0.292
17.8 ± 1.8 18.6 ± 3.4 0.435 0.714
24.7 ± 2.3⁎⁎ 25.9 ± 5.2⁎ 0.367 0.713
0.41 ± 0.12⁎⁎ 0.46 ± 0.09⁎⁎ 0.325 0.292
1.95 ± 0.34⁎⁎ 1.97 ± 0.37⁎ 0.907 0.749
= end-systolic index; SV = stroke volume; SI = stroke index; CO = cardiac output;
ricular mass; LVMI = left ventricular mass index; M/V ratio = ratio of left ventricular
lling percentage; TSR = torsion to (endocardial) strain ratio; PCr = phosphocreatine;
oints.
alysis.
Fig. 2. Box-plot of range and quartiles of the increase in LV mass between baseline and
16-week follow-up assessment, after endurance exercise training, expressed as a per-
centage of the baseline assessment in patient and control groups. LV = left ventricular.
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>1.6 and those b1.6.
There was no signiﬁcant effect of exercise training on the PCr/ATP
ratio in patients or controls (Fig. 3B), and no signiﬁcant difference in
the response to exercise between the groups (Table 4). There was a
trend towards an increase in the PCr/ATP ratio in patients following
exercise training (mean increase 11%, p = 0.260). PCr/ATP ratio in-
creased in six patients and decreased in four patients after exercise
training — at follow-up only four patients (40%) had a ratio b1.6
(Fig. 3B). Representative 31P MR spectra are shown (Fig. 4).Fig. 3. Spaghetti plot of the change in (A) LVMI and (B) PCr/ATP ratio in patients (red,
open squares) and controls (black, closed circles) following 16 weeks of endurance
exercise training. Solid lines represent individual participants; dotted lines represent the
correspondingmean group values; and vertical bars show the standard deviation at base-
line (left) and following exercise training (right) in the respective groups. LVMI = left
ventricular mass index; PCr = phosphocreatine; ATP = adenosine triphosphate; base-
line = initial assessment; post-exercise = follow-up assessment after completion of
16 week exercise training.3.9. Quality of life and disease burden
At baseline, patients had NMDAS scores averaging 16 ± 7, which
correlated with FIS score (r = 0.784, p = 0.007), but not urinary
m.3243A>G mutation load (r = 0.465, p = 0.176) or SF-12 scores
(r = 0.234, p = 0.477). After exercise training there was no signiﬁ-
cant change in NMDAS or SF-12 quality-of-life scores in patients
(Supplementary Table 3).3.10. Fatigue and autonomic function
FIS scores, both at baseline and after exercise training, were signif-
icantly increased in patients compared to controls (Table 5), but there
was no signiﬁcant effect of exercise on FIS score in either group; the
proportion of patients reporting excessive or severe fatigue at base-
line (40%) was unchanged following exercise training.
Consistent with the signiﬁcant elevation in resting heart rate, mean
RR intervalwas signiﬁcantly decreased in patients compared to controls
(Table 5). LF:HF-RRI was signiﬁcantly increased (mean increase 79%,
p = 0.03) in patients compared to controls, providing evidence of a
shift in sympatho-vagal balance, with effects predominantly driven
through an increase in sympathetic function (LFnu-RRI). Total diastolic
BPV (PSD-DBP) was signiﬁcant decreased in patients compared to con-
trols both before and after exercise training (Table 5). A signiﬁcant shift
in sympatho-vagal balance was again evident in patients compared
to controls (LF:HF-DPB), but driven here by a decrease in high frequen-
cy components, representing parasympathetic function (HFnu-DBP).
There was no signiﬁcant effect of exercise training on any HRV or BPV
parameter in either group.4. Discussion
The principal ﬁndings of this study of the effects of a 16-week en-
durance exercise training programme in patients harbouring the
m.3243A>G mutation compared to controls are: 1) endurance exer-
cise is safe with no deleterious effects on cardiac morphology and
function; 2) patients achieved similar proportional beneﬁts of train-
ing on cardio-pulmonary and haemodynamic parameters including
peak work capacity, peak oxygen uptake and anaerobic threshold,
with no evidence of disease progression or increased fatigue com-
pared to sedentary controls; 3) reduced exercise capacity detected
at baseline, is predominately mediated through peripheral skeletal
muscle dysfunction, rather than central cardiac factors; and 4) in-
creased sympathetic and decreased parasympathetic cardiovascular
autonomic activity pre- and post-exercise training suggests a role
for sympathetic over-activation in disease pathogenesis.
4.1. Reduced exercise capacity and skeletal muscle function
Consistentwith a previous case–control study of patients withmito-
chondrial disease [8], peak oxygen consumption, peak arterial–venous
Fig. 4. Phosphorus-31 magnetic resonance spectroscopy. Representative spectra from a patient carrying the m.3243A>G mutation (left) and a matched control subject (right) at
baseline (upper panels) and following completion of 16 week exercise training (lower panels) showing a difference in PCr concentration that is unaffected by exercise. Spectra
obtained from patient 3 (A) at baseline with PCr/ATP ratio 1.1, and (B) following exercise training with PCr/ATP 1.2 are displayed alongside spectra from the matched control
participant (C) at baseline with PCr/ATP 2.0, and (D) following exercise training with PCr/ATP 1.9. Spectra are presented as acquired before correction for heart rate, ﬂip angle
and blood content. PCr = phosphocreatine; ATP = adenosine triphosphate; ppm = parts per million.
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decreased in patients compared to untrained, sedentary controls, with
proportional reductions in peak exercise haemodynamic parameters.
Despite these facts, all patients completed the 16-week enduranceTable 5
Autonomic parameters and fatigue before and after exercise training.
Parameter Patients C
Baseline Follow-up p valuea B
Heart rate variability
Mean RRI (ms) 808 ± 101 854 ± 112 0.220
LFnu-RRI 68 ± 18 64 ± 19 0.711
HFnu-RRI 46 ± 18 48 ± 19 0.711
PSD-RRI 1472 ± 923 1976 ± 979 0.083 1
LF:HF-RRI 3.4 ± 0.9 2.8 ± 1.5 0.249
Blood pressure variability
LFnu-SBP 47 ± 9 44 ± 14 0.613
HFnu-SBP 18 ± 10 20 ± 15 0.729
PSD-SBP 9.0 ± 2.7 11.8 ± 7.1 0.169
LF:HF-SBP 3.9 ± 1.8 3.7 ± 2.7 0.330
LFnu-DBP 51 ± 14 47 ± 15 0.317
HFnu-DBP 13 ± 9 18 ± 11 0.081
PSD-DBP 4.9 ± 2.0 6.0 ± 3.7 0.088
LF:HF-DBP 6.1 ± 2.5 5.6 ± 2.1 0.278
Fatigue
FIS score 37 ± 34 34 ± 37 0.350
FIS = Fatigue Impact Scale; LF = low frequency; HF = high frequency; SBP = systolic bl
spectral density; RRI = RR interval. a p value represents the within group comparison of p
from mixed model repeated measures analysis. * p b 0.05 for patients vs. controls at equivaexercise training intervention (≥80% of the 48 scheduled sessions)
and no adverse events were reported. Participants remained medically
stable throughout the study with no deleterious changes in markers of
disease burden, skeletal muscle dysfunction or quality of life.ontrols Interaction p valueb
aseline Follow-up p valuea
891 ± 102⁎ 948 ± 119⁎ 0.128 0.568
54 ± 12⁎⁎ 48 ± 17⁎ 0.086 0.591
49 ± 22 58 ± 25 0.086 0.591
248 ± 824 2084 ± 1094 0.051 0.769
1.9 ± 1.7⁎ 1.9 ± 1.8 0.994 0.380
42 ± 13 38 ± 19 0.274 0.843
26 ± 8 28 ± 11 0.950 0.852
10.9 ± 6.3 12.5 ± 9.8 0.716 0.543
3.0 ± 2.6 2.8 ± 3.5 0.830 0.503
48 ± 15 43 ± 17 0.382 0.969
20 ± 11⁎ 29 ± 13⁎⁎ 0.006 0.767
7.1 ± 2.4⁎ 10.6 ± 5.6⁎⁎ 0.341 0.430
4.2 ± 2.1⁎ 3.9 ± 2.5 0.278 0.127
9 ± 11⁎ 5 ± 8⁎⁎ 0.087 0.928
ood pressure; DBP = diastolic blood pressure; nu = normalized units; PSD = power
aired before and follow-up time points. b p value represents group by time interaction
lent time points. ** p b 0.01 for patients vs. controls at equivalent time points.
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not reﬂected in indexed peak cardiac power output, which was not
statistically different to controls. This suggests that the reduction in
maximal exercise capacity and the associated symptom of exercise
intolerance in patients with the m.3243A>G mutation is related to
reduced peripheral ability of the skeletal muscle to extract oxygen
during exercise, rather than to a central cardiac limitation. This po-
tential mechanism is consistent with previous studies that have
reported preservation, or even elevation, of skeletal muscle oxygen
delivery [42–52], endothelial function, and oxygen unloading mecha-
nisms [42] in similar cohorts of patients with mitochondrial disease.
To our knowledge, this is the ﬁrst study to deﬁnitively exclude central
cardiac factors as a mediator of reduced exercise capacity in this
cohort of patients. Moreover, a similar blunted response to exercise
resulting from limited peripheral muscle oxygen extraction has been
reported in other disease states, where skeletal muscle dysfunction,
and indeed peripheral mitochondrial abnormalities, have been impli-
cated in the aetiology of reduced exercise capacity, including stroke
[53], heart failure [54–56], chronic obstructive pulmonary disease
(COPD) and chronic renal failure [57]. Interestingly, while the anaero-
bic threshold of patients in our study was reduced compared to con-
trols when expressed relative to predicted peak oxygen consumption,
there was no signiﬁcant difference in the absolute values or those
relative to the actual peak oxygen consumption between the groups.
This implies that skeletal muscle oxidative consumption may be
similar between the groups, suggesting that peripheral factors other
than mitochondrial oxidative metabolism may contribute to reduced,
exercise tolerance seen in patients with mitochondrial disease. Biopsy
studies have previously demonstrated an increase in skeletal muscle
oxidative capacity and respiratory chain enzymatic complex activities
with exercise training in patients withmitochondrial disease [8,9], but
further interventional studies would be necessary to examine other
skeletal muscle factors in this patient group.
Endurance exercise training improved peak work capacity, peak
oxygen consumption and anaerobic threshold in both patient and
control groups. This expected result is similar to previous aerobic exer-
cise training studies in patients with mitochondrial disease [6,9], and
occurred without an improvement in CPO or indexed CPO. This further
suggests that training improvements in exercise capacity, as well as the
baseline restrictions in these parameters, are manifestations of skeletal
muscle rather than cardiac involvement in mitochondrial disease. The
trend towards an improvement in peak arterio–venous oxygen differ-
ence at peak exercise in patients following a 16-week aerobic exercise
training intervention suggests an increased ability of the skeletalmuscle
to extract and utilise oxygen during aerobic exercise as a result of the
training programme. The ability of skeletal muscle to extract oxygen
during exercise represents an important and physiologically-relevant
surrogate marker of skeletal muscle mitochondrial function, and our
data suggest that although this parameter is blunted in patients with
mitochondrial disease due to the m.3243A>G mutation, it can be im-
proved by exercise training and that the magnitude of this improve-
ment is similar to that in untrained, sedentary controls. Similarly,
despite a much lower weight at baseline, patients showed a trend
towards an increase in lean body mass following exercise training,
whichmay representmorphological changes in skeletal muscle. Impor-
tantly, although all patients in this study reported the clinical feature
of exercise intolerance, and fatigue was noted in half, there was no
deleterious effect of exercise training on fatigue or reported quality of
life. This ﬁnding occurred despite an increase in exercise capacity in
patients, suggesting a clinical beneﬁt in this group.
4.2. Endurance exercise and cardiac remodelling
Our group has previously demonstrated, in similar cohorts, that pa-
tients harbouring the m.3243A>G mutation, without known cardiac
involvement on standard screening, display evidence of sub-clinicalhypertrophic remodelling compared to age- and gender-matched con-
trols [17,58]. The baseline results of this study support these ﬁndings
with decreased blood pool volumes, increased LVMI and M/V ratio,
and subtle abnormalities of systolic myocardial strains in patients com-
pared to controls. The direction and magnitude of exercise-induced
changes in LVM, LVMI andM/V ratio in both patient and control groups
are consistent with normal physiological responses to aerobic exercise
in untrained healthy controls [22–24]. Importantly, therewas no signif-
icant effect of group status on the proportional degree of hypertrophic
remodelling observed: patients and controls had similar responses to
exercise. We found no signiﬁcant effect of a 16-week endurance exer-
cise training programme on left ventricular volumes or cardiac systolic
or diastolic function, but acknowledge that these additional physiolog-
ical changes may not have been appreciated in this time frame.
Consistent with previous studies, we found abnormal cardiac bioen-
ergetics at baseline in patients harbouring the m.3243A>G mutation
[17]. In mitochondrial disease and other forms of inherited hypertro-
phic cardiomyopathy, several groups have suggested the primacy of
bioenergetic defects by detection of abnormalities in mutation carriers
without evidence of LVH [16,59,60]. Given that we also detected signif-
icant differences in cardiac remodelling, known to cause a reduction in
PCr/ATP ratio, we cannot comment on the temporal relationship of
these ﬁndings, but a reduced ratio has already been demonstrated to
have prognostic importance in a variety of forms of cardiomyopathy
[18]. Importantly therefore, wewere able to demonstrate, using 31P car-
diac MRS, that endurance exercise training had no further deleterious
effect on the abnormalmyocardial bioenergetics in our patients, despite
the expected and modest physiological increase in LVMI. Indeed, fol-
lowing aerobic exercise training, fewer patients had an abnormal PCr/
ATP ratio and the decreasedmean ratio of the patient groupwas less ev-
ident compared to controls. Taken together, these morphological, func-
tional and bioenergetic results suggest that a 16-week endurance
exercise training programme has no deleterious effects on the heart in
patients with mitochondrial disease due to the m.3243A>G mutation.
Given previous demonstrations of the beneﬁcial effects of endurance
exercise on exercise tolerance, quality of life and skeletal muscle func-
tion in this cohort of patients, this important result should allay fears
of any detrimental cardiac response to endurance exercise and poten-
tially enablemorewidespread adoption of a proven treatment in a pop-
ulation with currently limited therapeutic options.
4.3. Skeletal muscle oxidative capacity and sympathetic activation
Signiﬁcant differences between patients and controls in resting heart
rate and mean RR interval together with directionally opposing changes
in low and high frequency components of both HRV and diastolic BPV
provide evidence of a shift in the sympatho-vagal balance in patients
harbouring them.3243A>Gmutation. This ﬁnding is supported by an in-
creased LF:HF ratio for both RR interval and diastolic blood pressure,
suggesting increased sympathetic activity and a parallel reduction in
parasympathetic function in patients. This is consistentwith previous ob-
servations of resting sympathetic over-activity both in small studies of
patients with mitochondrial disease and in larger cohorts of patients
with other chronic diseases characterized by similar skeletal muscle dys-
function and exercise intolerance [61]. Our ﬁndings further corroborate
reports of a hyperadrenergic state in patients withmitochondrial disease
indicated by increased plasma concentration of noradrenaline in pa-
tients [42], and the high prevalence of sympathetic symptoms in this
population [62]. Chronic sympathetic activation is recognised as detri-
mental contributing to vasoconstriction, tissue hypoxia, inﬂammation,
oxidative stress, and impairment of muscle proton homeostasis; all fac-
tors thatmay lead to increased skeletal myopathy, hypertension and el-
evated cardiovascular risk [32,61,63]. The mechanisms underlying the
effects of chronic sympathetic activation are largely unknown, but sym-
pathetic outﬂow to skeletalmuscle,which is dependent on both barore-
ceptor and chemoreceptor regulation, is heightened selectively in
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recognised such as heart failure, COPD, essential hypertension and
end stage renal disease [64–67]. It has been postulated that overactivity
of skeletal muscle somatic afferents maintains an increased sympathet-
ic drive both during exercise and at rest, contributing to skeletal myop-
athy [68]. These nerve ﬁbres, whichmediate the exercise pressor reﬂex,
include metaboreceptors that are sensitive to ischaemic metabolites
during exercise, including lactic acid, and mechanoreceptors that are
primarily sensitive to stretch. Yet it has been shown that exercise intol-
erance and sympathetic activation are independent of lactic acidosis in
patients with mitochondrial disease [69,70]. We propose that the in-
creased sympathetic tone evident at baseline in patients, and the exag-
gerated neurovascular responses to exercise, with increased heart rate
at equivalent cardiopulmonary work capacities and time intervals,
may be at least partly due to increased skeletal muscle afferent mecha-
noreceptor sensitivity as seen in other chronic diseases with sympa-
thetic overactivity and exercise intolerance [71]. Indeed our data also
suggest a physiological upregulation of parasympathetic activity in pa-
tients in response to exercise training, similar in magnitude to the ef-
fect in control subjects. Further evaluation of the role of autonomic
dysregulation and impact on disease burden, phenotypic expression
and exercise intolerance in patients with mitochondrial disease is
warranted. Such studies may help to discern the major limitations of
exercise capacity in other chronic diseases associated with skeletal
myopathy, in which mitochondrial dysfunction has been implicated,
directing future therapeutic interventions.
4.4. Limitations
Although this study is the largest investigation of cardiac adapta-
tions to exercise performed to date in this patient group, it remains
limited in sample size, and duration, and was not designed to investi-
gate pathogenetic mechanisms or disease progression. In an already
extensive protocol, we did not make direct assessments of skeletal
muscle function or bioenergetics. We studied a relatively homoge-
nous cohort of patients, harbouring the single commonest mtDNA
point mutation, without known cardiac involvement: such patients
account for ~25% of our specialist clinic attendees yet we recognize
that our ﬁndings may not be generalizable to all patients with
mtDNA point mutations.
5. Conclusions
Our data represent the ﬁrst comprehensive evaluation of the car-
diac safety and efﬁcacy proﬁle of aerobic, endurance exercise training
in patients with m.3243A>G-related mitochondrial disease. We
have determined that endurance exercise training is safe in patients
harbouring the m.3243A>G mutation, and produces improvements
in clinical parameters of a similar magnitude and direction to those
observed in untrained, sedentary controls, and holds potential thera-
peutic beneﬁts for patients with mitochondrial disease. We also pro-
vide evidence of altered sympatho-vagal balance with sympathetic
over-activation in patients harbouring the m.3243A>G mutation.
This represents a further potential therapeutic target for pharmacolog-
ical intervention or improved vagal tone with exercise. Identiﬁcation
of an effective intervention that could slow or reverse progression of
skeletal muscle involvement in mitochondrial disease has the potential
to achieve signiﬁcant health gains with a substantial impact on patient
health and well-being. Our ﬁndings underpin the future translation of
effective exercise therapy into the clinical care of patients with mito-
chondrial disease.
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Appendix 1. Abbreviations
1-D 1-dimensional
31P phosphorus-31
2,3-DPG 2,3-disphosphoglycerate
AMARES accumulation method for accurate, robust and efﬁcient
spectra
ATP adenosine triphosphate
CSI chemical shift imaging
DNA deoxyribonucleic acid
DPG diphosphoglycerate
E/A early/late ﬁlling velocity
ECG electrocardiograph
FA ﬂip angle
FOV ﬁeld of view
HCM hypertrophic cardiomyopathy
LV left ventricular
LVH left ventricular hypertrophy
LVMI left ventricular mass index
MELAS mitochondrial encephalopathywith lactic acidosis and stroke-
like episode
MIDD maternally inherited diabetes and deafness
MRI magnetic resonance imaging
MRS magnetic resonance spectroscopy
mt-tRNA mitochondrial transfer RNA
mtDNA mitochondrial DNA
M/V left ventricular mass/end-diastolic volume
NMDAS Newcastle Mitochondrial Disease Adult Scale
PCr phosphocreatine
PDE phosphodiesters
ppm parts per million
RNA ribonucleic acid
SD standard deviation
SENSE sensitivity encoding
TE echo time
TR repetition time
TSR torsion to endocardial circumferential strain ratio
Appendix 2. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ijcard.2013.05.062.
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